Arcutis Biotherapeutics IncARQT
Price$26.43

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $462M+177.4% YoYTTM through 30 Jun 2026
Net Income $28.5MTTM through 30 Jun 2026
Free Cash Flow $39.2MTTM through 30 Jun 2026

Margins

Current
Gross Margin90.7%
EBITDA Margin9.0%
Operating Margin-8.6%
Net Margin6.2%

Returns

-1.3%ROE
-0.5%ROA
9.7%ROIC

Balance Sheet Health

Debt / Equity0.58x
Current Ratio2.68x
Net Debt-$114.6Mnet cash position
Cash & Equivalents$34.1M

Quality Metrics

Altman Z-Score6.50
Piotroski F-Score7 / 9
FCF Margin8.5%
Rule of 4024.7
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $376.1M
Diluted EPS$0.22TTM
'19'20'21'22'23'24'25
FY2025: $-0.13

Dividend

No dividend

Capital Allocation

R&D Spend$91M
Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.